WO2003026709A1 - Liquid mixture for use as a dressing spray - Google Patents

Liquid mixture for use as a dressing spray Download PDF

Info

Publication number
WO2003026709A1
WO2003026709A1 PCT/IB2001/001755 IB0101755W WO03026709A1 WO 2003026709 A1 WO2003026709 A1 WO 2003026709A1 IB 0101755 W IB0101755 W IB 0101755W WO 03026709 A1 WO03026709 A1 WO 03026709A1
Authority
WO
WIPO (PCT)
Prior art keywords
neomycin
mixture according
mixture
polymyxin
pharmaceutically
Prior art date
Application number
PCT/IB2001/001755
Other languages
French (fr)
Inventor
Mark Hite
Original Assignee
Mbs Multination Business Services (G.B.) Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mbs Multination Business Services (G.B.) Ltd. filed Critical Mbs Multination Business Services (G.B.) Ltd.
Priority to PCT/IB2001/001755 priority Critical patent/WO2003026709A1/en
Priority to EP02775026A priority patent/EP1429815A1/en
Priority to PCT/IB2002/003974 priority patent/WO2003026710A1/en
Publication of WO2003026709A1 publication Critical patent/WO2003026709A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0076—Sprayable compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A61L2300/406—Antibiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/04—Materials for stopping bleeding

Definitions

  • the present invention relates to a dressing spray composition for treating bleeding wounds on human beings or animals.
  • Object of the present invention is to provide a dressing spray for the treatment of bleeding wounds. Another object is to provide a dressing spray which is efficacious and can be applied by the general population. A still further object is to provide a spray which may be sold over the counter.
  • a liquid mixture for use as a dressing spray comprising a pharmaceutically efficacious amount of an anesthetic being either benzocaine or pramoxine hydrochloride a pharmaceutically efficacious amount of an antibiotic composition comprising polymyxin B or neomycin or bacitracin at least a pharmaceutically efficacious amount of a hemostatic compound and film forming components and at least a solvent, in which the aforesaid pharmaceutically components are dispersed or solubilized, for forming a film adhering to and covering the wound when sprayed onto it.
  • an anesthetic being either benzocaine or pramoxine hydrochloride
  • an antibiotic composition comprising polymyxin B or neomycin or bacitracin at least a pharmaceutically efficacious amount of a hemostatic compound and film forming components and at least a solvent, in which the aforesaid pharmaceutically components are dispersed or solubilized, for forming a film adhering to and covering
  • the inventive mixture has the advantage that pain is alleviated, infections by bacteria prevented and bleeding stopped.
  • the wound is protected from the environment by the film forming components sprayed onto the wound.
  • a further advantage of the mixture is that it can be sold over-the-counter as the components contained in the mixture are approved for over-the-counter use.
  • Benzocaine is present in a concentration between 10% and 30% (w/ v), preferably between 15% and 25% (w/v), and most preferably at about 20 % (w/v). The aforementioned concentrations alleviate pain very effectively.
  • pramoxine hydrochloride may be used, pramoxine hydrochloride may be present in the range between 1 and 25 mg/ml, preferably between 5 and 15 mg, and most preferably between 8 and 12 mg/ml liquid mixture.
  • the antibiotic neomycin is present in the mixture in a concentration between 0.5 and lOmg neomycin, preferably between 2 and 5 mg neomycin, and most preferably between 3 and 4 mg neomycin per 1 ml liquid mixture. These concentrations have proved to be very efficacious.
  • polymyxin between 5'000 and 15O00 units of polymyxin, preferably between 8000 and 12000, and most preferably about lO'OOO units of polymyxin B in 1 ml can be used in the liquid mixture as the antibiotic.
  • the best results are achieved if a combination of at least two of the antibiotics mentioned in claim 1 are used.
  • neomycin and polymyxin B are used in the mixture as they have a synergistic effect when used together.
  • the anesthetic compound, the antibiotics are most preferably solubilized or dispersed in styptic collodion. Styptic collodion is e.g. described in the Merck Index, 12 th edition, 1996.
  • Styptic collodion has the advantage that it contains film forming components and also hemostatic components. Styptic collodion is particularly advantageous as this dressing has already been widely used in the past with few problems associated with its use. It further does not occlude the injury completely as the film formed from it has microscopic holes.
  • Styptic collodion comprises nitrocellulose, camphor, caster oil, tannic acid, and at least a solvent.
  • the solvent may be ether or ethanol or a combination of it. Other readily evaporatable solvents may also be used. If a mixture of ether and ethanol is used, they may be present in a ratio between 1:1 to 4:1. In such a solvent mixture the active pharmaceutical components used in the mixture are readily solubilized.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Materials Engineering (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A novel liquid mixture for use as dressing spray for the treatment of bleeding wounds comprises a pharmaceutically efficacious amount of an anesthetic being either benzocaine or pramoxine hydrochloride, a pharmaceutically efficacious amount of an antibiotic composition comprising polymyxin B or neomycin or bacitracin, at least a pharmaceutically efficacious amount of a hemostatic compound and film forming components and at least a solvent, in which the aforesaid pharmaceutically components are dispersed or solubilized, for forming a film adhering to and covering the wound when sprayed onto it.

Description

Liquid Mixture for use as a Dressing Spray
The present invention relates to a dressing spray composition for treating bleeding wounds on human beings or animals.
Object of the present invention is to provide a dressing spray for the treatment of bleeding wounds. Another object is to provide a dressing spray which is efficacious and can be applied by the general population. A still further object is to provide a spray which may be sold over the counter.
According to the invention these and other objects are achieved by a liquid mixture for use as a dressing spray comprising a pharmaceutically efficacious amount of an anesthetic being either benzocaine or pramoxine hydrochloride a pharmaceutically efficacious amount of an antibiotic composition comprising polymyxin B or neomycin or bacitracin at least a pharmaceutically efficacious amount of a hemostatic compound and film forming components and at least a solvent, in which the aforesaid pharmaceutically components are dispersed or solubilized, for forming a film adhering to and covering the wound when sprayed onto it. The above novel mixture is particularly efficacious for the treatment of bleeding wounds. The inventive mixture has the advantage that pain is alleviated, infections by bacteria prevented and bleeding stopped. In addition, the wound is protected from the environment by the film forming components sprayed onto the wound. A further advantage of the mixture is that it can be sold over-the-counter as the components contained in the mixture are approved for over-the-counter use. Preferably, Benzocaine is present in a concentration between 10% and 30% (w/ v), preferably between 15% and 25% (w/v), and most preferably at about 20 % (w/v). The aforementioned concentrations alleviate pain very effectively. Alternatively, instead of Benzocaine, pramoxine hydrochloride may be used, pramoxine hydrochloride may be present in the range between 1 and 25 mg/ml, preferably between 5 and 15 mg, and most preferably between 8 and 12 mg/ml liquid mixture. Preferably the antibiotic neomycin is present in the mixture in a concentration between 0.5 and lOmg neomycin, preferably between 2 and 5 mg neomycin, and most preferably between 3 and 4 mg neomycin per 1 ml liquid mixture. These concentrations have proved to be very efficacious. Alternatively, between 5'000 and 15O00 units of polymyxin, preferably between 8000 and 12000, and most preferably about lO'OOO units of polymyxin B in 1 ml can be used in the liquid mixture as the antibiotic. However, the best results are achieved if a combination of at least two of the antibiotics mentioned in claim 1 are used. Preferably, neomycin and polymyxin B are used in the mixture as they have a synergistic effect when used together. The anesthetic compound, the antibiotics are most preferably solubilized or dispersed in styptic collodion. Styptic collodion is e.g. described in the Merck Index, 12th edition, 1996. Styptic collodion has the advantage that it contains film forming components and also hemostatic components. Styptic collodion is particularly advantageous as this dressing has already been widely used in the past with few problems associated with its use. It further does not occlude the injury completely as the film formed from it has microscopic holes.
Styptic collodion comprises nitrocellulose, camphor, caster oil, tannic acid, and at least a solvent. The solvent may be ether or ethanol or a combination of it. Other readily evaporatable solvents may also be used. If a mixture of ether and ethanol is used, they may be present in a ratio between 1:1 to 4:1. In such a solvent mixture the active pharmaceutical components used in the mixture are readily solubilized.

Claims

Claims
1. 1. Liquid Mixture for use as dressing spray for the treatment of bleeding wounds comprising a pharmaceutically efficacious amount of an anesthetic being either benzocaine or pramoxine hydrochloride a pharmaceutically efficacious amount of an antibiotic composition comprising polymyxin B or neomycin or bacitracin at least a pharmaceutically efficacious amount of a hemostatic compound and film forming components and at least a solvent, in which the aforesaid pharmaceutically components are dispersed or solubilized, for forming a film adhering to and covering the wound when sprayed onto it.
2. Mixture according to claim 1 wherein Benzocaine is present in a concentration between 10% and 30% (w/v), preferably between 15% and 25% (w/v), and most preferably at about 20 % (w/v).
3. Mixture according to claim 1 wherein the hemostatic compound and the film forming components are styptic collodion.
4. Mixture according to claim 3 wherein the styptic collodion comprises nitrocellulose, camphor, caster oil, tannic acid, and at least a solvent.
5. Mixture according to claim 4 wherein the solvent is a mixture of solvents comprising ether and ethanol.
6. Mixture according to claim 5 wherein ether and ethanol are present in a ratio between 1:1 to 4:1.
7. Mixture according to claim 1 wherein pramoxine hydrochloride is present in the range between 1 and 25 mg/ml, preferably between 5 and 15 mg, and most preferably between 8 and 12 mg/ml.
8. Mixture according to claim 1 wherein between 5O00 and 15O00 units of polymyxin, preferably between 8000 and 12000, and most preferably about lO'OOO units of polymyxin B are comprised in 1 ml of the liquid mixture.
9. Mixture according to claim 1 wherein neomycin is present in a concentration between 0.5 and lOmg neomycin, preferably between 2 and 5 mg neomycin, and most preferably between 3 and 4 mg neomycin per 1 ml liquid mixture.
10. Mixture according to claim 1 wherein polymyxin B and neomycin are used.
PCT/IB2001/001755 2001-09-26 2001-09-26 Liquid mixture for use as a dressing spray WO2003026709A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PCT/IB2001/001755 WO2003026709A1 (en) 2001-09-26 2001-09-26 Liquid mixture for use as a dressing spray
EP02775026A EP1429815A1 (en) 2001-09-26 2002-09-26 Mixture for use as a protective dressing
PCT/IB2002/003974 WO2003026710A1 (en) 2001-09-26 2002-09-26 Mixture for use as a protective dressing

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2001/001755 WO2003026709A1 (en) 2001-09-26 2001-09-26 Liquid mixture for use as a dressing spray

Publications (1)

Publication Number Publication Date
WO2003026709A1 true WO2003026709A1 (en) 2003-04-03

Family

ID=11004175

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2001/001755 WO2003026709A1 (en) 2001-09-26 2001-09-26 Liquid mixture for use as a dressing spray

Country Status (1)

Country Link
WO (1) WO2003026709A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9283187B2 (en) 2011-04-27 2016-03-15 Biom'up Hemostatic compositions
US11052172B2 (en) 2016-08-12 2021-07-06 Biom'up France SAS Hemostatic flowable

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966483A (en) * 1975-03-24 1976-06-29 Carpenter Chemical Company Method of formulating solution containing dispersed nitrocellulose
DE3133909A1 (en) * 1981-08-27 1983-03-17 Togal-Werk AG, 8000 München 2-Aminoheptane monoacetate
WO1988006884A1 (en) * 1987-03-09 1988-09-22 Lengyelne Horvath Gyoengyi A pharmaceutical composition used for the topical treatment of nail mycosis and a process for preparing same
EP0386960A2 (en) * 1989-03-07 1990-09-12 American Cyanamid Company Pharmaceutical compositions useful as drug delivery vehicles and/or as wound dressings
US5618515A (en) * 1992-08-19 1997-04-08 Blistex Inc. Aerosol spray composition for the treatment of dermal burns by cooling and anesthetizing the wound and valved container for dispensing same
US5725491A (en) * 1988-10-03 1998-03-10 Atrix Laboratories, Inc. Method of forming a biodegradable film dressing on tissue
WO2000010540A1 (en) * 1998-08-20 2000-03-02 3M Innovative Properties Company Spray on bandage and drug delivery system
WO2001037890A1 (en) * 1999-11-23 2001-05-31 Ever Power Holding Inc A propellant free spray-on skin patch composition for improving wound healing and for drug administration

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966483A (en) * 1975-03-24 1976-06-29 Carpenter Chemical Company Method of formulating solution containing dispersed nitrocellulose
DE3133909A1 (en) * 1981-08-27 1983-03-17 Togal-Werk AG, 8000 München 2-Aminoheptane monoacetate
WO1988006884A1 (en) * 1987-03-09 1988-09-22 Lengyelne Horvath Gyoengyi A pharmaceutical composition used for the topical treatment of nail mycosis and a process for preparing same
US5725491A (en) * 1988-10-03 1998-03-10 Atrix Laboratories, Inc. Method of forming a biodegradable film dressing on tissue
EP0386960A2 (en) * 1989-03-07 1990-09-12 American Cyanamid Company Pharmaceutical compositions useful as drug delivery vehicles and/or as wound dressings
US5618515A (en) * 1992-08-19 1997-04-08 Blistex Inc. Aerosol spray composition for the treatment of dermal burns by cooling and anesthetizing the wound and valved container for dispensing same
WO2000010540A1 (en) * 1998-08-20 2000-03-02 3M Innovative Properties Company Spray on bandage and drug delivery system
WO2001037890A1 (en) * 1999-11-23 2001-05-31 Ever Power Holding Inc A propellant free spray-on skin patch composition for improving wound healing and for drug administration

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DIRECTION OF THE COUNCIL OF THE PHARMACEUTICAL SOCIETY OF GREAT BRITAIN: "Acidum Tannicum, B.P.", THE BRITISH PHARMACEUTICAL CODEX, - 1911, Great Britain, XP002200816, Retrieved from the Internet <URL:http://www.ibiblio.org/herbmed/eclectic/bpc1911/acidum-tann.html> [retrieved on 20020528] *
MARYADELE J. O'NEIL, ANN SMITH, PATRICIA E. HECKELMAN: "The Merck Index, An Encyclopedia of chemical drugs, and biologicals", 1 January 2001, MERCK & CO., INC, WHITEHOUSE STATION, NJ, USA, XP002200817 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9283187B2 (en) 2011-04-27 2016-03-15 Biom'up Hemostatic compositions
US9662374B2 (en) 2011-04-27 2017-05-30 Biom'up Hemostatic compositions
US10046034B2 (en) 2011-04-27 2018-08-14 Biom'up Hemostatic compositions
US10342856B2 (en) 2011-04-27 2019-07-09 Biom'up Hemostatic compostions
US11052172B2 (en) 2016-08-12 2021-07-06 Biom'up France SAS Hemostatic flowable

Similar Documents

Publication Publication Date Title
Ward et al. Topical agents in burn and wound care
DE69933208T2 (en) USE OF COMPOSITIONS WITH ANTISEPTICA AND / OR WOUND HEALING EFFECTS FOR THE DEEP BREATHING WAY
DE69533724T2 (en) COMPOSITION FOR INACTIVATING SWEETENERS IN LIQUIDS
CA2334411A1 (en) Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma
US6555125B2 (en) Lesion and ulcer medication
RU94041223A (en) Agent for motoneuron disease treatment
US4735802A (en) Topical dermatological composition and method of treatment
WO2001070215A1 (en) Bactericidal preparation
US6352711B1 (en) Lesion and ulcer medication
JPH0761938A (en) Medicinal composition for external use consists of hydrophilic polysaccharides
DE102021200975A1 (en) Biologically-based wound closure preparation
SE1650162A1 (en) Antimicrobial and cleansing composition comprising a polymeric biguanide, EDTA, and surfactants.
WO2003026709A1 (en) Liquid mixture for use as a dressing spray
DE3443985A1 (en) Pharmaceutical preparations against mycotic and bacterial infections, which contain active ingredients which release zinc in ionised form
ITMI20090829A1 (en) OPHTHALMIC COMPOSITIONS FOR THE REITITIZATION, CYCLING, AND DISINFECTION OF THE EYE FABRICS
EP1429815A1 (en) Mixture for use as a protective dressing
EP1135116A1 (en) Use of poly (hexamethylene) biguanide for producing an agent for promoting the healing of uninfected wounds
US5496812A (en) Topical preparation of tolnaftate and hydrocortisone to treat fungal infections of the skin
KR960700069A (en) Wound Treatment Composition (WOUND HEALING COMPOSITION)
KR920703060A (en) Pharmaceutical Formulations
DE69922471T2 (en) Topical borneol and bismuth gallate containing pharmaceutical preparations for wound healing
CA2113080A1 (en) Topical composition containing penciclovir
US6838480B1 (en) Composition containing sucrafate and a topical anesthetic for humans and animals and method of use thereof
JPH11302184A (en) Nasal composition
JPH09502737A (en) New treatments for topical treatment of psoriasis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EE ES FI GB GD GE GH GM HU ID IL IN IS JP KE KG KP KR KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ PL PT RO RU SD SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZW AM AZ BY KG KZ MD TJ TM AT BE CH CY DE DK ES FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP